PDI, Inc. (PDII) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
Go back to PDI, Inc. (PDII) Reports In-Line Q2 EPS
August 13, 2015 4:27 PM EDT
PARSIPPANY, N.J., Aug. 13, 2015 /PRNewswire/ -- PDI, Inc. (NASDAQ: PDII) subsidiary Interpace Diagnostics announced today that both the ThyGenX Thyroid Oncogene Panel and ThyraMIR Thyroid miRNA Classifier, its molecular diagnostic tests for indeterminate thyroid nodules, are now covered by one of the largest independent Blue Cross Blue Shield plans that insures 3.3 million lives. This medical policy update, covering both ThyGenX and ThyraMIR, represents the first large commercial plan to cover ThyraMIR, a novel microRNA gene expression classifier launched earlier this year. Furthermore, it follows the recent announcement of coverage by Aetna for... More
August 13, 2015 4:01 PM EDT
PARSIPPANY, N.J., Aug. 13, 2015 /PRNewswire/ -- PDI, Inc. (NASDAQ: PDII) today reported financial and operational results for the second quarter and six months ended June 30, 2015.
Net revenue for the second quarter of 2015 was $36.3 million, an increase of 17.2% over $31.0 million in the second quarter of 2014. Net revenue from Commercial Services was $34.1 million for the... More
